Want to see AU:IMM full AI Analyst Report?
Top Page
Immutep Ltd
(Sydney:IMM)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.05
▼(-4.00% Downside)
Action:Downgraded
Date:06/03/26
The score is held down primarily by weak financial performance (persistent losses and negative cash flows) and bearish technicals (price below key moving averages with negative MACD). Low leverage and a relatively stable capital structure offer some support, but valuation is hard to assess meaningfully with a negative P/E and no dividend yield data.
Positive Factors
LAG‑3 platform and diversified pipeline
Owning a LAG-3–based platform with multiple clinical candidates provides durable strategic optionality. Multiple programs reduce binary risk from any single trial, support partnering/licensing opportunities, and align with long-term immuno‑oncology demand, sustaining R&D relevance over many quarters.
Negative Factors
Persistent negative margins
Consistent negative gross, EBITDA and net margins indicate the business has structural unprofitability at current stages. For a clinical-stage biotech this means extended reliance on financing until commercialization, making long‑term shareholder returns dependent on successful trials or value‑accretive partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
LAG‑3 platform and diversified pipeline
Owning a LAG-3–based platform with multiple clinical candidates provides durable strategic optionality. Multiple programs reduce binary risk from any single trial, support partnering/licensing opportunities, and align with long-term immuno‑oncology demand, sustaining R&D relevance over many quarters.
Read all positive factors
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$67.79M
Dividend YieldN/A
Average Volume (3M)4.11M
Price to Earnings (P/E)―
Beta (1Y)2.33
Revenue GrowthN/A
EPS Growth-73.11%
CountryAU
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$7.56M
Immutep Ltd Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a solu...
How the Company Makes Money
Immutep primarily makes money through partner-related biotechnology revenue rather than sales of approved products. Key revenue streams typically include: (1) licensing and collaboration agreements for its LAG-3 technology and/or specific drug can...
Immutep Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.98M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -31.23M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -83.33M | -62.88M | -44.54M | -42.88M | -31.87M | -17.49M |
| Net Income | -83.92M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 147.20M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 99.13M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 2.16M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 48.30M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 98.90M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.28M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.15M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | 59.60M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -210.50K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$4.83B | -442.68 | -1.72% | ― | 59.13% | -121.52% | |
54 Neutral | AU$2.66B | -19.57 | -16.10% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$357.79M | -97.40 | -15.96% | ― | 364.97% | 74.58% | |
45 Neutral | AU$55.00M | -0.92 | -93.08% | ― | 116.02% | 75.56% | |
41 Neutral | AU$41.63M | -0.38 | -134.65% | ― | ― | 62.72% | |
40 Underperform | AU$67.79M | -0.80 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:IMM
Immutep Ltd
0.05
-0.21
-81.54%
AU:IMU
Imugene
0.09
-0.18
-67.92%
AU:MSB
Mesoblast Limited
2.23
-0.06
-2.62%
AU:SPL
Starpharma Holdings Limited
0.79
0.68
638.32%
AU:TLX
Telix Pharmaceuticals
16.19
-0.70
-4.14%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.01
-50.00%
Immutep Ltd Corporate Events
Immutep’s Sarcoma Quality-of-Life Data Accepted for ESMO 2026
Jul 23, 2026
Immutep has had an abstract accepted for presentation at the ESMO Congress 2026 in Madrid, highlighting health-related quality of life data from the investigator-initiated Phase II EFTISARC-NEO trial. The study evaluates its first-in-class MHC Cla...
Immutep Wins Fourth U.S. Patent for Key Cancer Immunotherapy Combination
Jul 14, 2026
Immutep Limited has secured its fourth U.S. patent covering the use of its lead immunotherapy candidate, eftilagimod alfa, in combination with PD-1 or PD-L1 pathway inhibitors for cancer treatment. The new patent, which expires in January 2036, bu...
Immutep Posts Strong NSCLC Survival Data as It Probes Phase III Setback
Jul 12, 2026
Immutep reported mature overall survival data from the INSIGHT-003 Phase I trial, showing median overall survival of 30.9 months in first-line non-squamous NSCLC patients treated with efti plus pembrolizumab and chemotherapy, including those with ...
JPMorgan Group Ceases to Be Substantial Holder in Immutep
Jun 30, 2026
JPMorgan Chase Co and its affiliates have notified Immutep Ltd that they have ceased to be substantial holders in the company as of 26 June 2026. The change reflects a series of transactions and securities lending activities across multiple JPMor...
JPMorgan Chase Ceases to Be Substantial Holder in Immutep
Jun 16, 2026
JPMorgan Chase Co. and its affiliates have notified Immutep Ltd that they have ceased to be a substantial holder in the company as of 11 June 2026, following changes in their relevant interests and trading activities involving Immutep’s ord...
JPMorgan Ceases to Be Substantial Holder in Immutep Ltd
Jun 9, 2026
JPMorgan Chase Co. and its affiliates have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 5 June 2026, following a series of transactions involving securities lending, rehypothecation, and principa...
Regal Partners Exits as Substantial Shareholder in Immutep
Jun 9, 2026
Immutep Ltd has disclosed that Regal Partners Limited and its associated entities have ceased to be substantial shareholders in the company. The change follows a series of on-market transactions in early June 2026, including several large share sa...
Immutep Links Eftilagimod Immune Activation to Longer Survival in Late-Stage Cancer
May 27, 2026
Immutep reported a pooled analysis of five clinical trials showing that late-stage cancer patients receiving 30 mg subcutaneous eftilagimod alfa plus standard-of-care therapies had significantly increased absolute lymphocyte counts and a median ov...
JPMorgan Entities Exit Substantial Holder Status in Immutep
May 10, 2026
JPMorgan Chase Co. and its affiliates have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 6 May 2026. The change follows a series of securities lending, rehypothecation, and proprietary trading tra...
Immutep Faces Nasdaq Bid-Price Deficiency but Retains Listings as It Seeks Compliance
Apr 30, 2026
Immutep Limited has received a notice from Nasdaq that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00 per share, after trading below that threshold for 30 consecutive business days throu...
Immutep Halts Key Lung Cancer Trial but Pipeline Advances on Solid Cash Base
Apr 30, 2026
Immutep has discontinued its pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer after an interim futility analysis showed the eftilagimod alfa combination arm underperformed the control arm, prompting an orderly wind-down a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.